You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202161 - 202170 of 207728 results
  1. Vaccination Against West Nile Virus

    SBC: L2 DIAGNOSTICS LLC            Topic: N/A

    DESCRIPTION (provided by applicant): A commercially viable recombinant subunit vaccine to prevent West Nile virus infection is the overall objective of this project. West Nile virus was isolated for the first time in North America in 1999. In less than three years, the geographical distribution of the virus expanded dramatically in the United States. A vaccine will be an important complement to ...

    SBIR Phase I 2003 Department of Health and Human ServicesNational Institutes of Health
  2. Vaccination against Zika virus infection using mosquito NeSt1 protein

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    Arthropod-borne viruses (arboviruses) present a substantial threat to human and animal health worldwide. They are transmitted by hematophagous arthropods, in which mosquitoes are one of the main transmitters. The mosquito specie, Aedes aegypti, is the primary mosquito vector of several widely spread arboviruses as zika, dengue or West Nile viruses. Mosquitoes transmit these pathogens by inoculatin ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  3. VACCINATION BY TOPICAL APPLICATION OF CONDENSED DNA

    SBC: COPERNICUS THERAPEUTICS, INC.            Topic: N/A

    N/A

    SBIR Phase I 2000 Department of Health and Human ServicesCenters for Disease Control and Prevention
  4. Vaccination with purified, cryopreserved, infectious Plasmodium vivax sporozoites

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Plasmodium vivax (Pv) is the 2nd most important human malaria parasite, causing gt 80 million cases annually. However, efforts to prevent and control Pv malaria face major challenges of drug resistance and repeated relapses from dormant forms. Moreover, Pv vaccine development has been impeded, because Pv parasites cannot be grown in continuous in vitro culture. ...

    SBIR Phase I 2012 Department of Health and Human ServicesNational Institutes of Health
  5. Vaccine Adjuvant for Rapid Tolerance Induction in Allergy Patients

    SBC: TRIA BIOSCIENCE CORP.            Topic: NIAID

    DESCRIPTION (provided by applicant): Allergy is a major cause of illness and disability with an estimated 40-50 million people afflicted in the US alone. AIT provides long-term benefits for the patient and its need for optimization creates a compelling business opportunity. There is a very strong rationale to develop GLA for allergy based on its superior drug profile to MPL, a related TLR4 agonist ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Vaccine Adverse Event Reporting System (VAERS) Application for Mobile Devices

    SBC: Global Health Data Systems, LLC            Topic: N/A

    A mobile computing application will be developed for Apple iOS and Google Android based mobile devices. This application will be targeted towards healthcare providers who make routine use of mobile devices in their daily work. The application will be capable of capturing all information required for submission to the Vaccine Adverse Event Reporting System (VAERS) and securely transmitting the info ...

    SBIR Phase II 2013 Department of Health and Human ServicesCenters for Disease Control and Prevention
  7. VACCINE AGAINST HAEMOPHILUS INFLUENZAE TYPE B

    SBC: Synergen Inc            Topic: N/A

    THIS RESEARCH WILL LEAD TO THE DEVELOPMENT OF A VACCINE THAT CAN BE USED TO PROTECT YOUNG CHILDREN AGAINST INFECTIONS CAUSED BY HAEMOPHILUS INFLUENZAE TYPE B (HIB). THE VACCINE WILL BE BASED ON THE PILI THAT FACILITATE THE ORGANISM'S ADHERENCE TO THE NASOPHARYNGEAL EPITHELIUM. ANTIBODIES PRODUCED IN RESPONSE TO THE VACCINE WILL BIND TO HIB PILI, PREVENTING ADHERENCE AND COLONIZATION, AND THEREBY L ...

    SBIR Phase I 1989 Department of Health and Human Services
  8. Vaccine Against Primate Immunodeficiency Retroviruses

    SBC: Allergene            Topic: N/A

    SIV infection of rhesus macaques serves as a valuable model for HIV infection in humans. Both virusthrough the CD4 T-lymphocyte receptor and are infectious and cytopathic for CD4+ T-lymphocytes and mviruses are genetically closely related: SIV shares approximately 50 percent homology with HIV-1 andhomology with HIV-2. In SIV- infected rhesus macaques, as in HIV-infected humans, a predominantly asi ...

    SBIR Phase I 1995 Department of Health and Human Services
  9. Vaccine Approaches to Treatment of Hepatitis C Infection

    SBC: Cytel Corp.            Topic: N/A

    The overall aim of our studies is to derive a potential HCV vaccine, based on the induction of HCV-To do so, we will identify a synthetic formulation composed of at least two A2-restricted CTL epitopconserved regions of the HCV genome. Such formulation will also contain universal T helper epitopesdemonstrated to be efficacious in inducing specific A2-restricted CTL responses in vivo, utilizing Hmi ...

    SBIR Phase I 1995 Department of Health and Human Services
  10. Vaccine Approaches to Treatment of Hepatitis C Infection

    SBC: Cytel Corp.            Topic: N/A

    The overall aim of our studies is to derive a potential HCV vaccine, based on the induction of HCV-To do so, we will identify a synthetic formulation composed of at least two A2-restricted CTL epitopconserved regions of the HCV genome. Such formulation will also contain universal T helper epitopesdemonstrated to be efficacious in inducing specific A2-restricted CTL responses in vivo, utilizing Hmi ...

    SBIR Phase II 1998 Department of Health and Human Services
US Flag An Official Website of the United States Government